Welcome to the e-CCO Library!

DOP62: Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Chanchlani, N.(1);Lin, S.(1);Thomas, A.(1);Hamilton, B.(1);Nice, R.(2);Chee, D.(1);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP62: Medication use is increased in the decade prior to IBD diagnosis: A nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Linéa Bonfils
Created: Friday, 14 July 2023, 2:22 PM
DOP62: Medication use is increased in the decade prior to IBD diagnosis: A nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bonfils, L.(1)*;Karachalia Sandri, A.(1);Juul Poulsen, G.(1);Agrawal, M.(1,2);Ward, D.J.(1);Jess, T.(1,3);Colombel, J.F.(2);H. Allin, K.(1,3);
Created: Friday, 14 July 2023, 10:43 AM
DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Fiorino1, M. Allocca1, D. Gilardi1, M. Alfieri1, P. Danieli1, F. Furfaro1, G. Roda1, L. Loy1, A. Zilli1, S. Radice1, L. Peyrin-Biroulet2, S. Danese1

Created: Thursday, 30 January 2020, 10:12 AM
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort study
Year: 2019
Source: ECCO '19 Copenhagen
Authors: G. Pineton de Chambrun1, B. Pariente2, P. Seksik3, R. Altwegg1, L. Vuitton4, C. Stefasnescu5, S. Nancey6, A. Aubourg7, M. Serrero8, L. Peyrin-Biroulet9, J. Filippi10, S. Viennot11, V. Abitbol12, M. Boualit13, A. Boureille14, J. Moreau15, A. Buisson16, X. Roblin17, M. Nachury2, M. Zappa18, J. Lambert19, Y. Bouhnik5, GETAID-MICA studygroup1
Created: Friday, 22 February 2019, 9:41 AM
Last Modified: Wednesday, 27 February 2019, 4:37 PM by ECCO Administrator
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Guillaume Pineton de Chambrun
Created: Tuesday, 28 May 2019, 3:32 PM
Natural history, Crohn’s disease, Montreal Classification, MRI, Adalimumab, Anti-TNF agents, Penetrating disease, Abscess, Outcome measures
Files: 1
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trial
Year: 2020
Source: ECCO'20 Vienna
Authors: Gionata Fiorino
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP63: Mortality in Pediatric-onset Immune-Mediated Inflammatory Disease – A Nationwide Study.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Jansson, Sabine
Created: Tuesday, 30 April 2024, 5:03 PM
DOP63: Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Volkers, A.(1);Straatmijer, T.(1);Duijvestein, M.(2);Sales, A.(1);Levran, A.(1);van Schaik, F.(3);Jeroen, M.(4);Gecse, K.(1);Ponsioen, C.(1);Grootjans, J.(1);Hanzel, J.(1);Tack, G.(5);Jansen, J.(6);Hoentjen, F.(7);de Boer, N.(1);van der Marel, S.(8);Dijkstra, G.(9);Oldenburg, B.(3);Löwenberg, M.(1);van der meulen, A.(4);D'Haens, G.(1); on behalf of the IBD center of Amsterdam and the Dutch Initiative on Crohn and Colitis (ICC)
Created: Friday, 11 February 2022, 3:52 PM
DOP63: The Toronto IBD global endoscopic reporting (TIGER) score is well correlated with fecal calprotectin and IBD Disk in Ulcerative Colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zittan, E.(1,2);Steinhart, A.H.(3); Aran, H.(1);Milgrom, R.(3); Koifman, E.(1);Gralnek, I.M.(1); Zelber-Sagi, S.(2); Silverberg, M.S.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP63: Time Trends of Environmental and Socio-economical Factors in Patients with Inflammatory Bowel Disease over 40-year of Different Therapeutic Eras; results from a Population-based Cohort from Western Hungarian between 1977-2020, The Hygiene hypothesis revisited.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wetwittayakhlang, P.(1);Gonczi , L.(2);Lakatos , L.(3);Golovics , P.(4);Pandur , T.(5);David , G.(3);Erdelyi , Z.(3);Szita , I.(3);LakatosPhD, P.L.(6)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. WONG1, M. Bursavich2, N. Blanco1, A. Camblin1, L. Cappellucci1, R. Cohen1, D. Cui3, M. Krumpoch1, C. Zhong2, K. Hahn2, D. Lee3, B. Lippa2, F.Y. Lin4, A. Lugovsky5, M. McShea4, S. Mostafavi4, T. Moy1, A. Sullivan6, D. Troast2, L. Wang1, B. Rogers2

Created: Thursday, 30 January 2020, 10:12 AM
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Jamie Wong
Created: Tuesday, 23 June 2020, 5:40 PM
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Jamie Wong
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP64: Endoscopically injected allogeneic mesenchymal stromal cells alter the mucosal immune cell compartment in patients with ulcerative proctitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Ouboter, L.(1,2);Barnhoorn, M.(2);Plug, L.(2);van Pel, M.(1,3);Zwaginga, J.J.(4);Roelen, D.(1);Pascutti, F.(1);Koning, F.(1);Hawinkels, L.(2);Verspaget, H.(2);van der Meulen - de Jong, A.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L-Y. Mak*1, L. Chen2, T. Tong2, S. Lau2, W-K. Leung2

Created: Friday, 22 February 2019, 9:41 AM